Skip to content

We are currently experiencing some technical difficulties which may result in you experiencing longer than usual wait times on our telephone and chat channels. We apologise for the inconvenience but ask you to hold once in the queue as we will get to your call and resolve your query.

 

Transforming biosimilar switches for the NHS

Biosimilar switches can save the NHS millions, but administrative burden often delays these savings by months. This case study, published in PM Healthcare Journal, details how Sciensus and Gloucestershire Hospitals NHS Foundation Trust co-designed an automated service that transformed biosimilar transitions while removing the prescribing and administrative burden from NHS teams.

The result: A biosimilar switch completed in 3 months instead of 6-12 months, unlocking an additional £500k in savings.

What you’ll learn:

  • How automated prescribing using Sciensus pharmacists removes NHS administrative burden
  • Time savings: 75+ hours saved per 650 patients
  • Performance data: 92.5% biosimilar uptake at GHFT vs 52.8% nationally
  • The governance framework ensuring patient safety
  • How digital systems enable seamless switching while NHS clinicians focus on patient care

Download the full case study published in PM Healthcare Journal, a peer-reviewed quarterly publication sharing UK-wide best practice and innovation in pharmacy and healthcare.

Sciensus

About Sciensus

Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.

Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.

Learn more